dasatinib / Generic mfg. - LARVOL DELTA

Dasatinib and Quercetin in Patients With Relapsed, Refractory Multiple Myeloma Receiving CAR-T Therapy: First Report From the Safety Run-in of the Phase II DART Trial (IMS 2026) - P2 | "In the safety run-in of the DART trial, D+Q with cilta-cel was feasible and showed a safety profile consistent with cilta-cel alone, and no new signals associated with D+Q. Updated clinical and correlative results including additional TIS analysis in bone marrow biopsy will be reported."

CAR T-Cell Therapy • Clinical • P2 data • Cardiovascular • Hematological Malignancies • Hypertension • Infectious Disease • Multiple Myeloma • Neutropenia • Pneumonia • Respiratory Diseases • B3GAT1 • CD14 • KLRG1

Case Report: Clinical response to TKI therapy in T-cell acute lymphoblastic leukemia with rare ABL1 rearrangement. (PubMed, Front Oncol) - "Dasatinib (75 mg/m2/day) was added concurrently with CAM chemotherapy...This paper presents the second reported case to date of TKI treatment for T-cell acute lymphoblastic leukemia harboring the ZBTB16::ABL1 fusion. Following a review of the relevant literature on ABL1-rearranged T-ALL, we conclude that the accumulation of additional cases is essential to better characterize this rare molecular subtype and to guide evidence-based treatment decisions."

Journal • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • CNS Disorders • Hematological Malignancies • Hepatology • Leukemia • Liver Failure • Oncology • Pediatrics • Rare Diseases • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • Transplantation • ABL1 • CD7 • ZBTB16

Dasatinib and Quercetin in Patients with Relapsed, Refractory Multiple Myeloma Receiving CAR-T Therapy: First Report from the Safety Run-in of the Phase II DART Trial (IMS 2026) - P2 | "In the safety run-in of the DART trial, D+Q with cilta-cel was feasible and showed a safety profile consistent with cilta-cel alone, and no new signals associated with D+Q. Updated clinical and correlative results including additional TIS analysis in bone marrow biopsy will be reported."

CAR T-Cell Therapy • Clinical • P2 data • Cardiovascular • Hematological Malignancies • Hypertension • Infectious Disease • Multiple Myeloma • Neutropenia • Pneumonia • Respiratory Diseases • B3GAT1 • CD14 • KLRG1

A Rare Case of Concurrent Futibatinib-Induced Esophagitis and Colitis in Advanced Intrahepatic Cholangiocarcinoma (ACG 2026) - "Case Description/ A 61-year-old man with hypertension and metastatic FGFR2 fusion/rearrangement-positive ICC initially received first-line gemcitabine, cisplatin, and durvalumab followed by gemcitabine/durvalumab maintenance with subsequent disease progression...Among TKIs, dasatinib carries the highest risk of colitis, characterized by colonic erosions and lymphocytic infiltration...CT Abdomen and pelvis with contrast Figure: Figure 2. EGD showed erosive esophagitis in lower third of esophagus"

Clinical • Metastases • Biliary Cancer • Cardiovascular • Cholangiocarcinoma • Gastroenterology • Gastrointestinal Disorder • Hypertension • Immunology • Oncology • Solid Tumor • FGFR2

Refractory Dasatinib-Induced Pancolitis: A Case of Dual Biologic Failure (ACG 2026) - "Infectious workup revealed enteropathogenic E. coli, treated with azithromycin without resolution...Repeat colonoscopy demonstrated severe pancolitis (left-predominant) with normal terminal ileum; pathology showed active focal colitis with rare cytomegalovirus (CMV) inclusions, treated with valganciclovir...Notably, this colitis proved exceptionally refractory, failing anti-integrin (vedolizumab) and escalated anti-TNF (infliximab) therapies before responding to anti-IL-23 inhibition (risankizumab-rzaa). Clinicians should maintain high suspicion for TKI-induced colitis in CML patients with chronic diarrhea, as early drug cessation and biologic rotation may be necessary for recovery. Figure: Serial colonoscopy images demonstrating severe, left-predominant dasatinib-induced pancolitis."

Clinical • Chronic Myeloid Leukemia • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Immunology • Infectious Disease • Inflammatory Bowel Disease • Leukemia • ABL1 • BCR • IL23A

Beyond Adenocarcinoma: The Diagnostic Challenge of an Atypical Pancreatic Mass Unmasking Systemic B-Cell Lymphoblastic Leukemia (ACG 2026) - "He was treated for a presumed leukemoid reaction with hydroxyurea/allopurinol, yielding hematologic improvement before discharge...The patient was started on Hyper-CVAD, dasatinib, and intrathecal chemotherapy...Figure: EUS of pancreatic lesion with FNB needle in view. Figure: MRI post-contrast image slice revealing exophytic mass in pancreas body."

IO biomarker • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • CNS Disorders • Hematological Malignancies • Hepatology • High-grade B-cell lymphoma • Leukemia • Lymphoma • Musculoskeletal Pain • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • BCL2 • CA 19-9 • CD20 • MME • PAX5 • PTPRC

Target Attainment and Clinical and Biochemical Parameters Associated with the Pharmacokinetics of 12 Tyrosine Kinase Inhibitors. (PubMed, Clin Pharmacokinet) - "Target attainment was suboptimal for most TKIs, supporting the need for TDM-guided optimisation and individualised dosing. Associations between TKI exposure and renal, hepatic, and haematological parameters further support personalised treatment strategies."

Journal • PK/PD data • Hematological Disorders • Oncology

Characterizing bleeding adverse events associated with BCR-ABL tyrosine kinase inhibitors: insights from FAERS reports. (PubMed, Front Oncol) - "Reports involving imatinib, dasatinib, nilotinib, ponatinib, and bosutinib as primary suspected drugs were identified. Gastrointestinal, neurological, and ocular haemorrhagic events accounted for the majority of detected signals. These findings provide real-world evidence regarding the characteristics of bleeding-related adverse events associated with BCR-ABL TKIs and may contribute to pharmacovigilance monitoring, individualized safety management, and future investigations of haemorrhagic toxicity during TKI therapy."

Adverse events • Journal • Cardiovascular • Cerebral Hemorrhage • Chronic Myeloid Leukemia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Ophthalmology • ABL1 • BCR

Use of receptor and nonreceptor tyrosine kinase inhibitors and Parkinson disease risk. (PubMed, Neurotherapeutics) - "This study investigated associations between Medicare Part D prescription fills prior to PD diagnosis for 7 rTK inhibitors (erlotinib, sorafenib, pazopanib, imatinib, sunitinib, nintedanib, and dasatinib) and 4 nrTK inhibitors (nilotinib, ibrutinib, ruxolitinib, and tofacitinib) and PD risk. Given the chemotherapeutic mechanisms of these medications, and the known cancer-PD inverse relationship, we performed a sensitivity analysis adjusting for relevant cancer subtypes, yielding a similar inverse association. Overall, the use of rTK and nrTK inhibitors was associated with a lower risk of developing PD, although there may be differential impact of this medication class depending on specific inhibition pathways."

Journal • CNS Disorders • Movement Disorders • Oncology • Parkinson's Disease

Therapeutic Targeting of Inflammaging and Emerging Strategies for Managing Age-Related Multimorbidity: A Narrative Review. (PubMed, Clin Interv Aging) - "Combinations such as dasatinib plus quercetin and the flavonoid fisetin have reduced circulating SASP factors in early studies. Senomorphic agents, including rapamycin and Janus kinase (JAK) inhibitors, represent an alternative strategy by suppressing SASP production while preserving cell viability...Supplementation with precursors such as nicotinamide riboside and nicotinamide mononucleotide has shown beneficial effects on vascular function and metabolic health in early human studies...Repurposed metabolic medications including metformin, sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists also exhibit anti-inflammatory effects...Despite progress, translating these findings into clinical practice remains challenging because validated biomarkers are limited, trial designs are complex, and long-term safety data are still needed. Future collaborative research will help evaluate combination strategies and precision approaches targeting..."

First-in-human • IO biomarker • Journal • Review • Cardiovascular • Inflammation • IL1B • IL6 • TNFA

Dual-Driver Myeloproliferative Neoplasm: Concurrent p190 BCR::ABL1 CML and JAK2 V617F Mutation: A Case Report and Literature Review. (PubMed, Case Rep Hematol) - "The patient received first-line asciminib and was subsequently transitioned to dasatinib, with the BCR::ABL1/ABL1 ratio declining from 88.5% at diagnosis to 0.79% at most recent assessment. The admixed megakaryocytic atypia superimposed on myeloid hyperplasia reflected the coexistence of two drivers. Comprehensive profiling, including high-sensitivity RT-PCR capable of detecting the p190 isoform and concurrent JAK2 testing, is essential for accurate diagnosis, prognostication, and therapy selection in these rare dual-driver cases."

Journal • Chronic Myeloid Leukemia • Essential Thrombocythemia • Fibrosis • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Myeloproliferative Neoplasm • Oncology • Thrombocytopenia • Thrombocytosis • ABL1 • BCR • JAK2

Successful Cytotoxic Chemotherapy-Free Bridging to Hematopoietic Stem Cell Transplantation With Dasatinib and Prednisolone/Blinatumomab for Relapsed Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. (PubMed, Pediatr Blood Cancer) - No abstract available

Journal • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Pediatrics • Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation Achieves Durable Remission in Blast-Phase Chronic Myeloid Leukemia Presenting as Early T-Cell Precursor Acute Lymphoblastic Leukemia. (PubMed, EJHaem) - "The patient responded to treatment with dasatinib and Hyper CVAD. However, the BCR::ABL1 transcript levels remained positive, and the patient demonstrated resistance to switching to ponatinib and other agents...HSCT following remission induction therapy, inclusive of TKIs, may enhance prognosis for patients with blast phase CML presenting as ETP-ALL. The authors have confirmed clinical trial registration is not needed for this submission."

Journal • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • Transplantation • ABL1

DDR1 sustains ferroptosis resistance in pancreatic ductal adenocarcinoma via SLC40A1-mediated iron homeostasis. (PubMed, Oncogene) - "Crucially, combining Dasatinib and DHA treatment synergistically inhibits tumor growth in vivo by reactivating ferroptosis, as evidenced by increased 4-HNE accumulation and decreased Ki67 expression. These findings identify DDR1 as a key regulator of iron metabolism and ferroptosis in PDAC, suggesting that dual targeting of DDR1 and ferroptosis represents a promising therapeutic strategy."

Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • DDR1 • SLC40A1

A design approach for bitopic kinase inhibitors. (PubMed, Nature) - "PonatiLink-2 outperforms clinically relevant treatments in mouse models of BCR::ABL1-driven cancer, both in combination with dasatinib against wild-type BCR::ABL1 and as a single agent against ponatinib-resistant disease. These findings indicate that the bitopic design approach is a promising strategy for developing potent, well-tolerated clinical inhibitors of ABL1 and other targets."

Journal • Cardiovascular • Hematological Malignancies • Leukemia • Oncology • EGFR

Prolonged molecular control during intermittent reduced-intensity blinatumomab maintenance in a transplant-ineligible patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia and IKZF1 deletion. (PubMed, Clin Transl Immunology) - "A 64-year-old man with Ph+ ALL harbouring a heterozygous IKZF1 deletion relapsed while receiving dasatinib, with emergence of an ABL1 E255K/V mutation...Intermittent reduced-intensity blinatumomab maintenance guided by serial MRD monitoring was feasible and associated with durable molecular control in a transplant-ineligible patient with high-risk Ph+ ALL. This strategy merits prospective evaluation."

Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Transplantation • ABL1 • CD8 • IKZF1

AT2 Cell Senescence Increases Susceptibility to ARDS-Like Injury in a Sin3a-Deficient Mouse Model (ERS 2026) - "Sftpc-CreER Sin3a-flx/flx (Sin3a-LOF) mice received tamoxifen (TMX) to delete Sin3a in AT2 cells...Senolytic dasatinib plus quercetin (DQ) was given on days 35–48...In Sin3a-LOF mice with senescence-associated pulmonary fibrosis, profibrotic AT2 cells impaired type I IFN-mediated inflammatory responses and induced profibrotic macrophages, leading to sustained neutrophil activation during LPS challenge. These findings provide insight into mechanisms of acute exacerbation in interstitial lung disease."

Preclinical • Acute Respiratory Distress Syndrome • Fibrosis • Immunology • Inflammation • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases

Senolytic treatment during normothermic machine perfusion dampens ischemia reperfusion injury in old livers (TTS 2026) - " Isolated livers from old male Sprague Dawley rats (12 months) were treated with a perfusate solution supplemented with a combination of Dasatinib (2 μM) and Quercetin (20 μM) (D&Q) during 6 hours of NMP... Together, these data demonstrate for the first time that senolytic treatment during NMP is feasible and effective in dampening age-specific IRI which may be applicable not only for livers but older organ transplantation in general."

Cardiovascular • Hepatology • Liver Failure • Reperfusion Injury • Solid Organ Transplantation • CDKN1A • IL17A • IL6 • MMP3 • TNFA

Cellular Senescence Drives Age-Related Resistance to Costimulatory Blockade in Transplantation (TTS 2026) - " Aged C57Bl/6 mice (18-month) were pre-treated with senolytics—Dasatinib+Quercetin, "D/Q"—or vehicle (control) for 2 months, before undergoing fully-mismatched heterotopic heart transplantation from young (3-month) Balb/c donors... Senescent cell depletion with senolytics dramatically improves CTLA4-Ig efficacy in aged recipients, with graft survival nearing that of young mice. These findings identify senescence as a major driver of age-related resistance to costimulatory blockade. The upregulation of PD-1 checkpoint may play a critical mechanistic role, serving as a potential target for augmenting co-stimulatory blockade in aged recipients."

IO biomarker • Transplantation • CD8 • PD-L2

Dasatinib for Cranial Nerve Palsy Following Cilta-Cel (IMS 2026) - "Dasatinib represents a potentially novel therapeutic option for the management of certain CAR-T related toxicities. We treated 8 patients who experienced Cilta-cel related CNPs with a Dasatinib containing approach. The timing of initial improvement observed gives potential support for dasatinib having CAR T activity modifying effect while high rate of recurrence after initial improvement indicates that dasatinib related modification appeared short lived."

Hematological Malignancies • LCK

Impact of Posterior Reversible Encephalopathy Syndrome on Hospitalization and Mortality in Tyrosine Kinase Inhibitor-Treated Patients With Hematologic Malignancies: A Real-World Propensity-Matched Analysis (SOHO 2026) - " Using the TriNetX Global Collaborative Network (170 healthcare organizations), we identified TKI-treated patients (imatinib, dasatinib, bosutinib, ibrutinib, or erlotinib) who developed PRES within 1 year of initiation (cohort 1, n = 135) vs TKI-treated controls without PRES (cohort 2, n = 69764), excluding those with cocaine use disorders or hypertensive urgency/emergency. TKI-treated patients, including those receiving CML-directed BCR-ABL1 inhibitors, who developed PRES faced a nearly 2-fold increased hazard of hospitalization (HR, 1.799) and nearly 3-fold increased hazard of death (HR, 2.683) compared to propensity-matched controls, with median survival reduced to 1758 days versus not reached. PRES should be recognized as a high-stakes complication rather than a transient neurological event. Given the markedly shortened time to first hospitalization (190 vs 1404 days), early vigilance for PRES in TKI-treated patients is warranted."

Clinical • Real-world • Real-world evidence • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • BCR

Simultaneous induction of differentiation and senescence in cardiac fibroblasts by TGF-β1: effects of senotherapeutics drugs. (PubMed, Front Pharmacol) - "Given that TGF-β1 is a central mediator of CF-to-CMF differentiation and can induce senescence in various cell lines, we investigated whether it simultaneously triggers both processes in neonatal rat CFs, and whether the senotherapeutics Navitoclax and Dasatinib + Quercetin modulate the viability of senescent CMFs. TGF-β1 simultaneously promotes CF differentiation into CMFs and induces senescence, resulting in a sustained pro-fibrotic and inflammatory phenotype. Senotherapeutics treatment attenuates senescent CMFs, supporting its potential as a therapeutic strategy to mitigate cardiac fibrosis."

Journal • Cardiovascular • Fibrosis • Immunology • Inflammation • CDKN1A • IL10 • IL1B • IL5 • IL6 • RB1 • TGFB1 • VCAM1

Synthesis and characterization of l-arginine-grafted chitosan nanoparticles for intranasal Dasatinib delivery and brain targeting. (PubMed, Nanomedicine) - "Intranasal administration achieved a high brain accumulation of 3.84 ± 0.28 μg/mL, drug targeting index (DTI) of 7.24 and drug targeting percentage (DTP) of 86.2%. The innovative integration of La-mediated cell penetration with intranasal nose-to-brain delivery provides a promising translational platform for improving DTB delivery to GBM."

Journal • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. (PubMed, Leukemia) - "Among them, IKZF1 deletion was associated with poor prognosis in patients treated with imatinib-based or dasatinib-based regimens. In a multivariate analysis, dasatinib therapy, lack of achievement of 3-month complete molecular response, and the presence of IKZF1 status were significantly associated with poor OS. The differential impact of IKZF1 was largely restricted to patients given Hyper-CVAD plus ponatinib; dasatinib-based regimens had unfavorable outcomes regardless of the molecular abnormalities."

Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • IKZF1

PHASE 3 STUDY OF INTENSIVE CHEMOTHERAPY WITH OR WITHOUT DASATINIB IN PATIENTS WITH CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA – FINAL ANALYSIS OF THE AMLSG 21-13 TRIAL (EHA 2025) - P3 | "Two previous phase 1b/2 trials in CBF-AML have shown the combination of chemotherapy with dasatinib to be safe and associated with favorable outcome.Aims: We present results from the final analysis of the randomized, open-label, phase 3 trial of intensive chemotherapy with or without dasatinib in adult patients with CBF-AML (NCT02013648).Patients received "3+7" induction therapy (optional 2nd cycle if PR only after the 1st cycle), followed by 4 cycles of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, days 1-3; in the investigational arm, patients received dasatinib 100 mg QD on days 8-21 in induction, and on days 4-28 in consolidation cycles, followed by single-agent dasatinib 100 mg QD for one year (or until relapse). In patients with CBF-AML, the addition of dasatinib to intensive chemotherapy failed to improve EFS and OS overall as well as in patient subgroups. The frequency of adverse events was higher in the investigational arm."

Clinical • P3 data • Acute Kidney Injury • Acute Myelogenous Leukemia • Atrial Fibrillation • Cardiovascular • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Nephrology • Neutropenia • Oncology • Pneumonia • Renal Disease • Respiratory Diseases • Septic Shock • KIT • RUNX1 • RUNX1T1